CD274 and non-small cell lung carcinoma: Studies were considered eligible if they met the following criteria: 1) Population: adults with PD-L1-positive NSCLC with histologic confirmation; 2) Intervention: pembrolizumab monotherapy or combination therapy in Phase II/III randomized controlled trials; 3) Control: chemotherapy; 4) Outcomes: OS, PFS, overall response rate (ORR), and safety outcomes; 5) Language: English-language publications.